Valuation: Positron Corporation

Market Cap 57.48M 51.36M 47.92M 43.52M 81.97M 5.56B 82.58M 576M 225M 2.83B 216M 211M 9.09B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 56.34M 50.34M 46.97M 42.66M 80.35M 5.45B 80.95M 564M 221M 2.77B 212M 207M 8.91B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
1 day-2.54%
1 week-2.13%
Current month-2.13%
1 month-2.58%
3 months+2.94%
6 months-3.85%
Current year+4.79%
1 week 1.72
Extreme 1.72
1.94
1 month 1.59
Extreme 1.59
2
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-2.54%-2.13%+24.11%+45.83% 57.48M
+0.83%-1.92%+22.79%+32.80% 245B
+1.34%-1.38%+4.66%+0.58% 154B
+2.41%+1.94%-5.99%+40.19% 146B
-1.45%-4.74%-56.64%-20.22% 60.26B
-0.81%-0.63%+11.81%+16.39% 49.44B
-0.14%-1.87%+22.03%+52.83% 47.67B
-0.71%+1.62%-21.26%-18.65% 48.04B
-0.35%-1.03%-7.75%+34.78% 45.74B
-0.10%-0.77%+36.95%+63.05% 42.84B
Average -0.46%-1.85%+3.07%+24.76% 83.89B
Weighted average by Cap. -0.22%-2.10%+4.59%+23.26%

Financials

2024 2025
Net sales 588K 525K 490K 445K 838K 56.83M 844K 5.89M 2.3M 28.9M 2.21M 2.16M 92.92M 461K 412K 385K 349K 658K 44.64M 663K 4.62M 1.81M 22.7M 1.73M 1.69M 72.98M
Net income -2.38M -2.13M -1.98M -1.8M -3.39M -230M -3.42M -23.83M -9.31M -117M -8.93M -8.74M -376M -10.6M -9.47M -8.84M -8.03M -15.12M -1.03B -15.23M -106M -41.5M -522M -39.81M -38.95M -1.68B
Net Debt 1.42M 1.27M 1.19M 1.08M 2.03M 138M 2.05M 14.27M 5.57M 70.08M 5.35M 5.23M 225M -1.14M -1.02M -947K -860K -1.62M -110M -1.63M -11.38M -4.45M -55.9M -4.27M -4.17M -180M
Projected Income Statement - Annual - Positron Corporation
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
07/10/26 $1.750 -2.54% 21,557
06/10/26 $1.796 -2.41% 42,382
05/10/26 $1.840 +4.25% 32,995
02/10/26 $1.765 -1.51% 6,059
01/10/26 $1.792 +0.22% 4,636
  1. Stock Market
  2. Stocks
  3. POSC Stock